FDA Approves Astrazeneca's Seroquel For Maintenance Treatment In Bipolar Disorder
AstraZeneca announced that the U.S. Food and Drug Administration (FDA) has approved SEROQUEL (quetiapine fumarate) for the maintenance treatment of patients with bipolar I disorder, as adjunct to lithium or divalproex. SEROQUEL is approved by the FDA for the treatment of schizophrenia, and is also the only single agent approved by the FDA for the treatment of both depressive episodes in bipolar disorder and acute manic episodes associated with bipolar I disorder1, 2.
Benefits Of Omega 3s Still Unclear For Bipolar Disorder
Despite intriguing findings that omega 3 fatty acid supplements could alleviate depression symptoms, there is still not enough evidence to say whether omega 3s are useful treatments for people with bipolar disorder, according to a review of recent studies.
Perceptual Switch Rates With Ambiguous Structure-from-motion Figures In Bipolar Disorder
Most people believe that the way we see things is affected by how we feel emotionally. Does our mood really change what we see or do individuals with certain genetic traits always tend to see things differently, regardless of their mood? Earlier research suggested that people with bipolar mood disorder might alternate their perception more slowly when looking at ambiguous figures.
Alcohol Dependence May Respond To Aripiprazole, Treatment For Bipolar Disorder And Schizophrenia.
* Aripiprazole is currently approved to treat bipolar disorder as well as schizophrenia. * A new study has found that it significantly and dose-dependently increases the sedative effects of alcohol and, to a lesser degree, decreases the euphoric effects of alcohol.
New Analysis Highlights Potential Of SEROQUEL For Long-term Treatment Of Bipolar Disorder
Results from a new analysis of two major clinical trials have shown that patients with bipolar disorder who received long-term treatment with SEROQUEL (quetiapine fumarate) plus a mood stabiliser were significantly less likely to have a mood event (manic, mixed or depressed) than patients on a mood stabiliser alone.
New Analysis Demonstrates Efficacy Of Seroquel Quetiapine Fumarate Maintenance Treatment For Bipolar I Disorder
Results from a combined analysis of two long term phase III clinical trials2, 3 have shown that patients with bipolar I disorder who received treatment with quetiapine plus a mood stabiliser showed a 70% reduction in the risk of recurrence of a mood event (manic, mixed or depressed) compared to patients on a mood stabiliser alone (HR=0.
Study Suggests Risperidone Long Acting Injection Combined With Standard Treatment Helped Delay Time To Relapse In Patients With Bipolar Disorder
Patients with frequently relapsing bipolar disorder had a significant delay in the time to an initial relapse when risperidone long-acting injection (RLAI) was combined with standard treatment, according to a new study. The study compared patients who received RLAI and standard treatment to those who received standard treatment combined with placebo.
Scientists Discover Chemical Signature Of Manic Depression
People with manic depression have a distinct chemical signature in their brains, according to a new study. The research, published in the journal Molecular Psychiatry, may also indicate how the mood stabilisers used to treat the disorder counteract the changes in the brain that it appears to cause.
ACADIA Announces Presentation Of Data On Pimavanserin Co-Therapy At The 14th Biennial Winter Workshop On On Schizophrenia And Bipolar Disorders
ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that Murray Rosenthal, D.
Astrazeneca Submits Seroquel XR For The Treatment Of Bipolar Mania And Bipolar Depression, And Seroquel R For The Treatment Of Bipolar Depression
AstraZeneca announced that the company has submitted applications in the European Union (EU) under the Mutual Recognition Procedure (MRP) for once-daily SEROQUEL XR(TM) (quetiapine fumarate) Extended-Release Tablets, seeking approval for the treatment of manic episodes associated with bipolar disorder and the treatment of depressive episodes associated with bipolar disorder.